What Does Recent Data Related to SGLT2 Inhibitors Mean for My Patients? Effect of Online Medical Education on Physician Knowledge and Competence

Presentation Number: MON 613
Date of Presentation: April 3rd, 2017

Amy Larkin*1, Michael LaCouture2 and Anne Le1
1Medscape Education, 2Medscape Education, Mount Laurel, NJ

Abstract

Background:

Busy clinicians find it challenging to stay up to date with new data, and the resulting knowledge gaps can lead to indecision and a lack of timely application of evidence-based therapies. We sought to determine if online continuing medical education (CME) could improve the clinical knowledge and competence of primary care physicians (PCPs) and diabetologists/endocrinologists (D/Es) regarding new data related to SGLT2 inhibitors.

Methods:

The CME activity was developed as an online video roundtable discussion between 3 experts in T2D management. We assessed the effects of education using a 4-question linked pre-/post-assessment study design. McNemar’s chi-squared test was used to assess if the mean post‐assessment score differed from the mean pre‐assessment score. P values are shown as a measure of significance; P values <.05 are statistically significant. Cramer’s V was used to calculate the effect size (<0.05 no effect; 0.06-0.15 small effect, 0.16-0.30 medium effect, >0.30 large effect). The activity launched on November 19, 2015 and data were collected through January 29, 2016. Participants who answered all pre-/post questions during this time period were included in analyses.

Results:

Baseline knowledge was higher among D/E compared to PCPs:

  • 30% of PCPs compared to 49% of D/Es recognized the effect of an SGLT2 inhibitor on body weight

  • 42% of PCPs compared to 69% of D/Es recognized recent clinical trial data on cardiovascular outcomes for an SGLT2 inhibitor

Significant overall improvements were seen for both the PCPs (n = 267; P < .05; medium effect V= 0.215) and D/Es (n = 122; P < .05; small effect V= 0.131) as a result of participation in the CME activity. Specific areas of improvements include:

  • 36% more PCPs (P < .05) and 29% more D/Es (P <.05) correctly identified the effect of an SGLT2 inhibitor on body weight

  • 32% more PCPs (P < .05) and 24% more D/Es (P <.05) correctly translated recent clinical trial data into appropriate patient education point related to genital mycotic infections

Post-assessment scores reveal continued educational gaps:

  • 32% of PCPs compared to 28% of D/Es failed to identify appropriate patient education point related to genital mycotic infections

  • 43% of PCPs compared to 26% of D/Es failed to recognize recent cardiovascular outcomes clinical trial data for an SGLT2 inhibitor

Conclusion:

This study demonstrates the success of a targeted educational intervention on improving knowledge and competence of PCPs and D/Es regarding new data related to SGLT2 inhibitors. Although baseline knowledge was lower among PCPs compared to D/Es, demonstrating a higher need for more foundational education for PCPs, both groups showed significant improvements in knowledge as a result of the education. Additional education on clinical trial data related to SGLT2 inhibitors is needed for both PCPs and D/Es given the low post-assessment scores.

 

Nothing to Disclose: AL, ML, AL